Phase 1 Lymphoma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing to sign a consent form, follow the study plan, and complete all required procedures
• Adults aged 18 or older, of any gender
• People diagnosed with a type of B-cell non-Hodgkin's lymphoma (a blood cancer) that tests positive for a protein called CD20, covering several specific subtypes, who have already received prior treatments that did not work — including at least one treatment containing a medicine that targets CD20 (confirm with trial site for which subtypes and how many prior treatments apply)
• People who have at least one measurable area of lymphoma that can be tracked on scans, meeting specific size requirements (confirm with trial site)
• People whose overall physical fitness is rated 0 to 2 on a standard medical scale, meaning they are able to carry out daily activities with little to no limitation
• People of childbearing potential who agree to use effective contraception and have no plans for pregnancy from the time of signing consent until 6 months after the last dose of the study drug
• People with an expected survival of at least 3 months

Who may not be able to join:

• People who currently have, or have previously had, lymphoma affecting the brain or spinal cord
• People who have had a donor stem cell transplant or other organ transplant at any point, or who have had their own stem cells transplanted within the 100 days before starting the study
• People who have received a live (weakened) vaccine within 4 weeks before starting the study, or who plan to receive one during the study
• People who have had another type of cancer within the past 5 years, with exceptions for certain fully cured skin cancers or cervical conditions, or any cancer that has been in complete remission for at least 5 consecutive years (confirm with trial site)
• People with active autoimmune diseases (such as lupus, rheumatoid arthritis, inflammatory bowel disease, or similar conditions) or a history of conditions likely to return — though some stable, low-level autoimmune conditions may be considered on a case-by-case basis by the research team
• People who have had major surgery within 28 days before starting the study, or who are expected to have major surgery during the study
• People who need regular high-dose steroid tablets or other immune-suppressing medicines within 7 days before starting the study or during the study (low-dose or locally applied steroids may be acceptable — confirm with trial site)
• People who have had an active blood clot in a deep vein or the lungs within the 6 months before screening
• People who currently have interstitial lung disease, a certain type of non-infectious lung inflammation, or active tuberculosis
• People with serious ongoing health conditions — such as diabetes or significant heart or brain/blood vessel disease — that are not well controlled with treatment
• People with certain heart conditions, including a weakened pumping function, moderate-to-severe heart failure, certain serious irregular heartbeats, an abnormal electrical reading of the heart (QTc interval) above specific thresholds, or a heart attack or heart surgery within the past 6 months (confirm with trial site for full details)
• People who test positive for HIV, or who have active hepatitis B or hepatitis C infection based on blood tests during screening
• People with severe, uncontrolled active infections such as blood poisoning or serious fungal or viral infections at the time of screening
• People who have had a severe allergic reaction (grade 3 or higher) to a similar type of medicine (a monoclonal antibody or large protein-based drug) in the past
• People who have taken part in another interventional clinical trial, or are currently enrolled in one, within 4 weeks before starting this study
• People with a known significant neurological or psychiatric condition, such as epilepsy or dementia, that may affect their ability to follow the study requirements
• People who are pregnant or breastfeeding
• People who have had a stroke or bleeding in the brain within the past 6 months
• People who have had active or confirmed bleeding in the digestive tract (such as from ulcers or enlarged veins in the oesophagus or stomach) within the past 6 months
• People whom the research team considers unsuitable for any other reason, including those whose disease appears to be progressing rapidly during the screening period

Important: Always verify eligibility with the trial site directly before applying.